Proposed Influenza Vaccination Recommendations for 2013-14

Lisa Grohskopf, MD, MPH
Influenza Division, NCIRD, CDC

Advisory Committee on Immunization Practices
June 20, 2013



Acknowledgements

Buddy Creech
Stephen Dreskin
Kathy Edwards
Chip Emmanuel
Neal Halsey

Donna Hummell

Robert Wood

Clinical Immunization Safety

Assessment Project (CISA)

Matt Greenhawt John Kelso

Karen Broder
Maria Cano
Penina Haber
Theresa Harrington
Tom Shimabukuro

Joe Bresee

Carolyn Bridges

Nancy Cox

Dan Jernigan

Lyn Finelli

Alicia Fry

Paul Gargiullo

Sam Graitcer

Erin Kennedy

Andrew Kroger

David Shay

Leslie Sokolow

Ray Strikas

Mark Thompson

Tim Uyeki

Updated information in 2013-14 ACIP Influenza Vaccination Statement

- Core recommendations, recently approved vaccines, new abbreviations discussed at February 2013 meeting
- New material since February 2013
 - Influenza vaccine virus strains selected for 2013-2014.
 - Additional new quadrivalent vaccine, Fluzone® Quadrivalent
 - Two proposed modifications to recommendations for persons with a history of egg allergy

Influenza Vaccine Viruses for 2013-14

□ Trivalent vaccines:

- an A/California/7/2009 (H1N1)-like virus,
- an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011 (A/Texas/50/2012), and
- a B/Massachusetts/2/2012-like virus (Yamagata lineage).

Quadrivalent vaccines:


 In addition to the above, will also contain a B/Brisbane/60/2008-like virus (Victoria lineage)

Recently-approved Influenza Vaccines

- Quadrivalent Live attenuated Influenza Vaccine (LAIV4)—Flumist® Quadrivalent (MedImmune)
- Quadrivalent Inactivated Influenza Vaccine (IIV4)—Fluarix® Quadrivalent (GSK)
- Trivalent Cell-culture based inactivated influenza vaccine (ccllV3)—Flucelvax® (Novartis)
- Trivalent Recombinant hemagglutinin vaccine (RIV3)—FluBlok® (Protein Sciences)
- Quadrivalent Inactivated Influenza Vaccine (IIV4)—Fluzone®
 Quadrivalent (Sanofi Pasteur)

Fluzone® Quadrivalent (IIV4)

- Sanofi Pasteur
- Licensed by the FDA in June 2013
- Indicated for persons 6 months and older
- Available in 0.25mL and 0.5mL prefilled syringes and 0.5mL single dose vials
- Included in table of available vaccines as an acceptable alternative to other licensed products used within indications



Influenza Vaccination for Persons with Egg Allergies--Proposed Modification #2

Addition of the following:

"For individuals who have no known history of exposure to egg, but who are suspected of being egg-allergic on the basis of previously performed allergy testing, consultation with a physician with expertise in the management of allergic conditions should be obtained prior to vaccination."

Summary of Items for Discussion or Vote

- Addition of Fluzone Quadrivalent to the Table of available vaccines
- Modification of the egg allergy algorithm to include RIV
- Addition of language to address persons with no history of egg exposure but questionable allergy testing

Thank You!

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

